The global radiofrequency ablation devices market accounted for USD 4.87 billion in 2023 and is expected to reach at USD 16.84 billion by 2034 with a CAGR of 11.94% during the forecast period 2024-2034. Increasing incidence of chronic & cardiovascular diseases (CVDs), growing inclination towards minimally invasive surgeries, rising elderly population, a heightened demand for efficient treatment, increase in healthcare-related spending, growing prevalence of chronic pain disorders such as arthritis & osteoporosis, improvements in healthcare infrastructure, surge in research & development efforts and growing introduction of innovative radiofrequency ablation devices are some of the key factors boosting the market growth.
Growing introduction of innovative radiofrequency ablation devices is predicted to boost the market growth during the forecast period. Radiofrequency ablation (RFA) is a medical procedure that utilizes heat radiation to alleviate pain and reduce the size of tumors and other abnormalities. Conditions such as chronic neck or back pain, as well as chronic venous insufficiency in the legs, are just a few examples of medical ailments that can be effectively treated using this method. For instance, in April 2022, Royal Philips introduced the newest version of its KODEX-EPD system, featuring improved imaging and mapping functions for RF ablation procedures. This includes the addition of the Tissue Engagement Viewer and compatibility with the Medtronic DiamondTemp ablation system.
By component, disposable equipment was the highest revenue-grossing segment in the global radiofrequency ablation devices market in 2023 owing to the reducing the risk of complications and the increasing introduction of new products by industry participants. Additionally, reusable equipment is predicted to grow at the fastest CAGR during the forecast period owing to the growing investment by major market players, and increasing approvals of novel devices. For instance, in June 2023, The U.S. Food and Drug Administration (FDA) has received a 510(k) application for NeuroOne Medical Technologies' OneRF Ablation System. NeuroOne Medical Technologies is committed to improving surgical alternatives and results for patients with neurological illnesses.
By application, surgical oncology was the highest revenue-grossing segment in the global radiofrequency ablation devices market in 2023 owing to the rising incidence of cancer, an uptick in research & development endeavors, and surge in technological advancements. Additionally, cardiology & cardiac rhythm management is predicted to grow at the fastest CAGR during the forecast period owing to the growing risk of developing Atrial Fibrillation (AF), increasing preference for the catheter ablation approach, and heightened introduction of advanced devices. For instance, in April 2022, AtriCure introduced the EnCompass Clamp as a component of its Isolator Synergy ablation system. Using synergy radiofrequency technology, this platform combines parallel closure, uniform pressure, and customizable power to maximize the effectiveness of simultaneous surgical ablations for the ablation of cardiac tissue during cardiac surgery.
By end-user, hospital was the highest revenue-grossing segment in the global radiofrequency ablation devices market in 2023 as hospitals serve as the primary location for RF ablation procedures, supported by favorable reimbursement policies & adequate infrastructure for conducting such procedures, and increasing introduction of new devices. For instance, in October 2022, Biosense Webster, Inc., a medical device company, unveiled the HELIOSTAR Balloon Ablation Catheter in Europe. This catheter is designed for catheter-based cardiac electrophysiological mapping of the atria, including stimulating and recording functions. Additionally, when paired with a compatible multi-channel RF generator, it is suitable for cardiac ablation procedures. Additionally, ambulatory surgery centers is predicted to grow at the fastest CAGR during the forecast period owing to the demand for ambulatory surgery centers (ASCs) is on the rise. These centers specialize in providing outpatient surgical procedures, including radiofrequency ablation, without the need for hospital admission. ASCs offer numerous advantages to both patients and healthcare providers, such as reduced costs, quicker recovery periods, increased convenience, and improved patient satisfaction levels.
North America region is anticipated for the highest revenue share during the forecast period owing to the widespread occurrence of cancer, rapid technological progress, increased government backing for quality healthcare, and rising approvals from regulatory agencies. For instance, in May 2023, The U.S. FDA has granted approval to Abbott Laboratories for its TactiFlex ablation catheter. This innovative catheter is utilized alongside a state-of-the-art RF ablation system to treat cardiac diseases such as atrial fibrillation and cardiac arrhythmia effectively. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing adoption of cutting-edge technologies such as multi-needle electrodes, which offer precision, portability, & cost-effectiveness, rising disposable income, enhancements in healthcare infrastructure, surge in prevalence of chronic disease, and heightened efforts towards expansion by market participants. For instance, in February 2022, Ramesh Hospitals inaugurated an upgraded cardiac electrophysiology laboratory in Vijayawada, India, equipped with advanced treatments including radiofrequency ablation, pacemakers, automatic implantable cardiac defibrillators, and more.
Growing introduction of innovative radiofrequency ablation devices is predicted to boost the market growth during the forecast period. Radiofrequency ablation (RFA) is a medical procedure that utilizes heat radiation to alleviate pain and reduce the size of tumors and other abnormalities. Conditions such as chronic neck or back pain, as well as chronic venous insufficiency in the legs, are just a few examples of medical ailments that can be effectively treated using this method. For instance, in April 2022, Royal Philips introduced the newest version of its KODEX-EPD system, featuring improved imaging and mapping functions for RF ablation procedures. This includes the addition of the Tissue Engagement Viewer and compatibility with the Medtronic DiamondTemp ablation system.
By component, disposable equipment was the highest revenue-grossing segment in the global radiofrequency ablation devices market in 2023 owing to the reducing the risk of complications and the increasing introduction of new products by industry participants. Additionally, reusable equipment is predicted to grow at the fastest CAGR during the forecast period owing to the growing investment by major market players, and increasing approvals of novel devices. For instance, in June 2023, The U.S. Food and Drug Administration (FDA) has received a 510(k) application for NeuroOne Medical Technologies' OneRF Ablation System. NeuroOne Medical Technologies is committed to improving surgical alternatives and results for patients with neurological illnesses.
By application, surgical oncology was the highest revenue-grossing segment in the global radiofrequency ablation devices market in 2023 owing to the rising incidence of cancer, an uptick in research & development endeavors, and surge in technological advancements. Additionally, cardiology & cardiac rhythm management is predicted to grow at the fastest CAGR during the forecast period owing to the growing risk of developing Atrial Fibrillation (AF), increasing preference for the catheter ablation approach, and heightened introduction of advanced devices. For instance, in April 2022, AtriCure introduced the EnCompass Clamp as a component of its Isolator Synergy ablation system. Using synergy radiofrequency technology, this platform combines parallel closure, uniform pressure, and customizable power to maximize the effectiveness of simultaneous surgical ablations for the ablation of cardiac tissue during cardiac surgery.
By end-user, hospital was the highest revenue-grossing segment in the global radiofrequency ablation devices market in 2023 as hospitals serve as the primary location for RF ablation procedures, supported by favorable reimbursement policies & adequate infrastructure for conducting such procedures, and increasing introduction of new devices. For instance, in October 2022, Biosense Webster, Inc., a medical device company, unveiled the HELIOSTAR Balloon Ablation Catheter in Europe. This catheter is designed for catheter-based cardiac electrophysiological mapping of the atria, including stimulating and recording functions. Additionally, when paired with a compatible multi-channel RF generator, it is suitable for cardiac ablation procedures. Additionally, ambulatory surgery centers is predicted to grow at the fastest CAGR during the forecast period owing to the demand for ambulatory surgery centers (ASCs) is on the rise. These centers specialize in providing outpatient surgical procedures, including radiofrequency ablation, without the need for hospital admission. ASCs offer numerous advantages to both patients and healthcare providers, such as reduced costs, quicker recovery periods, increased convenience, and improved patient satisfaction levels.
North America region is anticipated for the highest revenue share during the forecast period owing to the widespread occurrence of cancer, rapid technological progress, increased government backing for quality healthcare, and rising approvals from regulatory agencies. For instance, in May 2023, The U.S. FDA has granted approval to Abbott Laboratories for its TactiFlex ablation catheter. This innovative catheter is utilized alongside a state-of-the-art RF ablation system to treat cardiac diseases such as atrial fibrillation and cardiac arrhythmia effectively. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing adoption of cutting-edge technologies such as multi-needle electrodes, which offer precision, portability, & cost-effectiveness, rising disposable income, enhancements in healthcare infrastructure, surge in prevalence of chronic disease, and heightened efforts towards expansion by market participants. For instance, in February 2022, Ramesh Hospitals inaugurated an upgraded cardiac electrophysiology laboratory in Vijayawada, India, equipped with advanced treatments including radiofrequency ablation, pacemakers, automatic implantable cardiac defibrillators, and more.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Type, Material, Product, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Radiofrequency Ablation Devices Market Report 2023 - 2034
Radiofrequency Ablation Devices Market Analysis & Forecast by Component 2023 - 2034 (Revenue USD Bn)
- Capital Equipment
- Disposable Equipment
- Reusable Equipment
Radiofrequency Ablation Devices Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Cardiology & Cardiac Rhythm Management
- Gynecology
- Cosmetology
- Pain Management
- Surgical Oncology
Radiofrequency Ablation Devices Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Hospital
- Research Laboratories
- Ambulatory Surgery Centers
Radiofrequency Ablation Devices Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Radiofrequency Ablation Devices Market: Component Estimates & Trend Analysis
8. Radiofrequency Ablation Devices Market: Application Estimates & Trend Analysis
9. Radiofrequency Ablation Devices Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Radiofrequency Ablation Devices Market
12. Europe Radiofrequency Ablation Devices Market
13. Asia Pacific Radiofrequency Ablation Devices Market
14. Latin America Radiofrequency Ablation Devices Market
15. MEA Radiofrequency Ablation Devices Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Johnson & Johnson Services Inc.
- Abbott
- Stryker
- AngioDynamics
- Smith & Nephew
- Medtronic
- Boston Scientific Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 4.87 Billion |
| Forecasted Market Value ( USD | $ 16.84 Billion |
| Compound Annual Growth Rate | 11.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 7 |
